BACKGROUND: @entity1398 occurring in @entity1 receiving chemotherapy for solid @entity5 or @entity706 is usually of short duration, and therefore may have a better outcome compared to @entity1 with acute @entity1778 or @entity1 receiving myeloablative chemotherapy. AIMS: To review retrospectively the outcomes for @entity1398 occurring in @entity1 of the Medical Oncology Unit at our institution, and to identify factors associated with worse outcome, particularly prolonged admission or @entity204 . METHODS: We reviewed 102 episodes of @entity1398 occurring in 85 @entity1 treated between 1992 and 1994. Demographic factors, @entity5 -related factors and clinical aspects of the episodes were correlated with outcome. RESULTS: The median age was 60 years (range, 18-87), with 56 (55%) episodes occurring in females. Twenty-eight (27%) episodes occurred in @entity1 with @entity706 , with the remaining 74 (73%) occurring in @entity1 with solid @entity5 . At presentation, the median absolute neutrophil count (ANC) was 0.14 x 10(9)/L with a median duration of significant @entity1398 (ANC < 0.5 x 10(9)/L) of three days. The median duration of @entity221 was two days. Twenty-nine (28%) episodes had positive cultures; of these 11 had @entity582 . Forty-four (43%) episodes were classified as unexplained fevers. The remaining 29 episodes were associated with clinically documented infection but negative cultures. There was a high treatment success rate (81%) with first-line empirical antibiotics. Of 19 treatment failures, 13 were due to the necessity for antibiotic modification; the other six @entity1 died from infection. Factors associated with a worse outcome (including prolonged admission and @entity204 ) include: diagnosis of @entity706 ; increasing number of chemotherapy courses; early onset of @entity1398 ; @entity55 ; severe @entity551 ; and multiple co-morbidities. CONCLUSIONS: @entity1398 in adult @entity1 with solid @entity5 or @entity706 is associated with a relatively good outcome, possibly due to the short duration of @entity1398 . A future prospective study to validate the risk factors identified in this study would be useful for defining @entity1 at low risk for the adverse outcomes examined, in whom less intensive management for this condition may be possible.

XXXX in a medical oncology unit.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'Febrile neutropenia', 'febrile neutropenia'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukaemia'] @entity582 :: ('MESH:C531821', 'Disease') :: ['bacteraemia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever']
@entity1398 :: (MESH:D009503,Disease) :: ['Low-risk febrile neutropenia']
